Genmab A/S has announced topline results from its Phase 3 EPCORE DLBCL-1 trial showing that epcoritamab, a subcutaneous CD3xCD20 bispecific antibody, improved progression-free survival (PFS) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for high-dose chemotherapy and autologous stem cell transplant. The study demonstrated a hazard ratio of 0.74 (95% CI 0.60 to 0.92) for PFS and numerical trends across complete response rates and duration of response. However, overall survival (OS) did not reach statistical significance (HR: 0.96). Genmab and co-developer AbbVie plan to engage with regulators globally on next steps for potential label expansion.

Why epcoritamab’s PFS signal matters even without OS win

The most immediate takeaway from the EPCORE DLBCL-1 trial is that it marks the first time a bispecific antibody monotherapy has shown a statistically significant improvement in progression-free survival in a Phase 3 study of relapsed or refractory DLBCL patients. While overall survival did not cross the statistical bar, industry observers suggest this PFS signal represents an inflection point for the monotherapy class in aggressive lymphoma, especially in patients who lack curative transplant options.

The comparator arms—either rituximab plus gemcitabine and oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR)—represent investigator’s choice in a challenging post-chemo setting. Demonstrating superiority on PFS over these regimens builds a clinically relevant case for epcoritamab, especially given the growing aversion to cumulative chemotherapy toxicity in older or comorbid patients.

Even without a clear OS win, a PFS benefit in DLBCL has historically supported regulatory action and reimbursement consideration. The PFS improvement may translate into delayed need for next-line therapy, which has commercial and quality-of-life implications. Whether regulators will view the result as sufficient for label expansion without an OS advantage remains a pivotal question.

What the safety readout suggests about long-term viability

The adverse event profile observed in EPCORE DLBCL-1 appears consistent with prior data on epcoritamab and the broader class of T-cell engaging bispecifics. Cytokine release syndrome (CRS) and neurotoxicity risks remain inherent to the mechanism, though manageable through step-up dosing and monitoring protocols. Industry analysts note that subcutaneous administration is likely to be seen as an advantage relative to intravenous bispecific competitors, potentially reducing hospital burden and making outpatient administration more feasible.

However, clinicians tracking the field remain cautious about the long-term tolerability of chronic T-cell activation, especially in fixed-duration regimens. The current study does not appear to introduce new safety signals, but broader commercial success will hinge on scalability across community settings, where CRS management infrastructure may be more limited than in academic centers.

How epcoritamab compares with other bispecifics in the DLBCL space

Epcoritamab’s Phase 3 PFS win is a class-first for CD3xCD20 bispecific monotherapy, but it enters a competitive field where multiple players—including Roche’s glofitamab and Regeneron’s odronextamab—are racing to carve out differentiated niches. While glofitamab has already secured accelerated approvals, it has not yet demonstrated PFS improvement in a head-to-head Phase 3 setting.

What separates epcoritamab is its subcutaneous administration, fixed-duration treatment protocols in upcoming trials, and a broader push across both monotherapy and combination strategies. AbbVie’s co-commercialization rights provide distribution and global access leverage that few bispecific platforms can currently match.

Nonetheless, the bispecific class as a whole still faces adoption headwinds related to CRS management, sequencing decisions post-CAR-T, and lack of mature data in frontline DLBCL. Epcoritamab’s result may pressure competitors to accelerate late-stage programs or shift toward combo development strategies.

What this reveals about fixed-duration therapy strategies in hematologic malignancies

While EPCORE DLBCL-1 evaluated epcoritamab as a continuous monotherapy, Genmab and AbbVie are concurrently running two Phase 3 trials—EPCORE DLBCL-2 and DLBCL-4—that focus on fixed-duration regimens in both front-line and relapsed settings. Fixed-duration therapy has become a strategic goal across hematology, with BTK inhibitors and CD20 monoclonal antibodies increasingly being evaluated in time-limited combinations.

The expectation is that fixed-duration bispecific regimens could retain efficacy while reducing cumulative toxicities and improving quality-of-life metrics. This may also allow for more effective bridging to transplant or cellular therapies. However, clinical proof that fixed-duration bispecifics can maintain deep remission durability is still forthcoming.

If epcoritamab’s ongoing trials confirm durable responses without indefinite therapy, the product may shift market expectations for how bispecifics are positioned in the broader hematology treatment algorithm.

What regulators and payers will focus on as approval discussions begin

The lack of statistically significant OS improvement could become a gating issue in certain markets. Regulatory watchers suggest that in the absence of OS or patient-reported outcome superiority, health technology assessment agencies and payers may demand additional real-world evidence or long-term follow-up before granting broad reimbursement.

However, the meaningful PFS delta and the lack of viable alternatives for transplant-ineligible relapsed DLBCL patients provide a strong foundation for conditional or restricted approvals, especially in Europe. Genmab and AbbVie are likely to lean on the unmet need narrative while submitting full data at a future medical meeting and in regulatory filings.

What remains unclear is whether the EPCORE DLBCL-1 data will support label expansion into earlier lines of therapy—or if it will solidify epcoritamab’s role only in later-line salvage settings for now.

What this means for AbbVie’s oncology pipeline positioning

For AbbVie, the epcoritamab program is one of its most closely watched post-Humira oncology bets. With multiple CD20-targeting therapies in its portfolio, including venetoclax for chronic lymphocytic leukemia, AbbVie has staked a claim on B-cell malignancies as a commercial pillar beyond its immunology franchise.

The epcoritamab program provides AbbVie with an anchor bispecific asset that is flexible across monotherapy and combination indications. However, to fully justify the platform’s long-term value, the fixed-duration trials and frontline use cases will need to deliver.

The topline PFS win gives the co-commercialization alliance with Genmab renewed momentum, but AbbVie still faces structural challenges in hematologic oncology where competition, payer scrutiny, and delivery complexity have slowed uptake of even approved novel therapies.

What could complicate commercial uptake and clinical adoption

Despite the encouraging PFS signal, several unresolved issues may impact epcoritamab’s commercial ramp. The trial enrolled patients over a period that spanned the COVID-19 pandemic and the increasing availability of other novel agents—both of which may confound deeper interpretation of efficacy duration, adverse event reporting, and comparator arm performance.

There is also ongoing ambiguity around treatment sequencing in relapsed DLBCL. Bispecifics like epcoritamab are being used after or in place of CAR-T therapies in some geographies, but no universal standard has emerged. If CAR-T therapies move into earlier lines of treatment, bispecifics could find themselves squeezed into narrower late-line niches.

Manufacturing and distribution logistics also remain a concern for bispecific antibodies, particularly around supply chain reliability for subcutaneous formulations and cold chain transportation in global markets.

What clinicians and industry observers are watching next

Industry observers expect Genmab to present full results at a major hematology congress, which could clarify subgroup performance, duration of response, and safety stratification. Particular attention will be paid to outcomes in patients with multiple prior lines of therapy and to how epcoritamab performs across different comorbidity profiles.

Clinicians tracking the field are also awaiting longer-term data on relapse patterns post-epcoritamab and whether the drug primes or impairs patients for subsequent treatments, including CAR-T or transplant. These dynamics will influence real-world sequencing and reimbursement decisions.

The ongoing DLBCL-2 and DLBCL-4 trials—expected to read out in 2026—will likely define epcoritamab’s ultimate role in first-line and fixed-duration therapy. Until then, the topline PFS win serves as a meaningful milestone but not yet a definitive repositioning of the standard of care.

  AbbVie, bispecific antibodies, CD3xCD20, diffuse large B-cell lymphoma, DLBCL, Epcore DLBCL-1, EPCORE trials, epcoritamab, Genmab, hematologic malignancies